Overview
Meredith Wernick is a Radiation Oncologist in Baltimore, Maryland. Dr. Wernick is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Breast Cancer, Pleuropulmonary Blastoma, Prostate Cancer, and Familial Prostate Cancer. Dr. Wernick is currently accepting new patients.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
22 S Green St, Baltimore, MD 21201
Sibley Memorial Hospital
Aditya Halthore, MD, serves as Assistant Professor in the Department of Radiation Oncology and Molecular Radiation Sciences and Director of Safety and Quality at the Johns Hopkins University School of Medicine. Listen to Dr. Halthore's On Target podcast episode to learn more about his work. Dr. Halthore is an expert in proton therapy and specializes in genitourinary and thoracic cancers. His specific interests include prostate, bladder, lung, esophageal, and thymic cancers, and he is committed to developing personalized treatment strategies for every patient. Dr. Halthore was previously recognized as a Howard Hughes Medical Institute (HHMI)/National Institutes of Health (NIH) Scholar and his research interests include grant funded clinical trials focused on the novel utilization of radiation and imaging techniques, such as spatial fractionation (proton GRID) therapy for the treatment of bulky cancers. He is also involved in using dual-energy CT and functional MRI studies that aim to improve functional radiation planning and the assessment of radiation-induced changes. As an educator, Dr. Halthore serves as Course Director for the Johns Hopkins Proton Therapy Certificate Program. He actively participates in student, resident, and fellow lectureship and mentorship across the Johns Hopkins health system. Dr. Halthore participates in several national-level initiatives including as a member of the American Society of Therapeutic Radiation Oncology (ASTRO) Guidelines Subcommittee and as a board member and ASTRO liaison to the Medical Dosimetry Certification Board (MDCB). Dr. Halthore is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Prostate Cancer, Small Cell Lung Cancer (SCLC), Marginal Zone Lymphoma (MZL), and Familial Prostate Cancer.
Sibley Memorial Hospital
Marie Kate Gurka, M.D., is a radiation oncologist in the Department of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital and a clinical associate in the Department of Radiation Oncology at The Johns Hopkins Hospital. Dr. Gurka has expertise in radiation treatment for breast cancer and gynecologic cancers. Dr. Gurka earned her medical degree from Virginia Commonwealth University and completed a residency in radiation oncology at Georgetown University Hospital. She previously served as an instructor in the Department of Radiation Oncology at University of Louisville and has conducted both clinical and basic science research. Her work has been recognized by the American Society for Radiation Oncology (ASTRO), and the American Society of Clinical Oncology (ASCO), and it has been cited in various lectures, research articles, and textbooks. Washingtonian Magazine and Bethesda Magazine have repeatedly named Dr. Gurka a Top Doctor. Selected Publications Oermann EK, Bhandari R, Chen V, Lebec G, Gurka M, Lei S, Chen L, Suy, S, Azumi N, Berkowitz F, Kalhorn C, McGrail K, Collins BT, Jean W, Collins SP. Five Fraction Image-Guided Radiosurgery for Primary and Recurrent Meningiomas. Frontiers in Radiation Oncology. 2013; 3: 213. Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ. Stereotactic Body Radiation Therapy with Concurrent Full-Dose Gemcitabine for Locally Advanced Pancreatic Cancer: A Pilot Trial Demonstrating Safety. Radiation Oncology. 2013; 8: 44. Gurka MK, Kim C , Carroll J, Charabaty A, Haddad M, Jackson P, Collins SP, Marshall J, Pishvaian MK, Unger KR. Stereotactic Body Radiation Therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma. American Journal of Clinical Oncology. 2014; 152-157. Gurka MK, Horne ZD, Ju A, Chen L, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP. Hematuria Following Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer. Radiation Oncology. 2015; 10:44. Gurka MK, Pender D, Chuong P, Fouts B, Sebelov A, McNally M, Mezera M, Woo SY, McNally R. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. Journal of Controlled Release. 2016; 231:60-67. Dr. Gurka is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Breast Cancer, Intraductal Papilloma, Gliomatosis Cerebri, and Marginal Zone Lymphoma (MZL).
Wellspan Medical Group
Sherif Yacoub is a Radiation Oncologist in York, Pennsylvania. Dr. Yacoub is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Prostate Cancer, Laryngeal Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Yacoub is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Breast CancerDr. Wernick isDistinguished. Learn about Breast Cancer.
- Pleuropulmonary BlastomaDr. Wernick isDistinguished. Learn about Pleuropulmonary Blastoma.
- Advanced
- Anal CancerDr. Wernick isAdvanced. Learn about Anal Cancer.
- Familial Prostate CancerDr. Wernick isAdvanced. Learn about Familial Prostate Cancer.
- HER-2 Positive Breast CancerDr. Wernick isAdvanced. Learn about HER-2 Positive Breast Cancer.
- Intraductal PapillomaDr. Wernick isAdvanced. Learn about Intraductal Papilloma.
- Lung CancerDr. Wernick isAdvanced. Learn about Lung Cancer.
- Muscle Invasive Bladder CancerDr. Wernick isAdvanced. Learn about Muscle Invasive Bladder Cancer.
- Experienced
- Adult Soft Tissue SarcomaDr. Wernick isExperienced. Learn about Adult Soft Tissue Sarcoma.
- ALK-Positive Non-Small Cell Lung CancerDr. Wernick isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- AngiosarcomaDr. Wernick isExperienced. Learn about Angiosarcoma.
- AstrocytomaDr. Wernick isExperienced. Learn about Astrocytoma.
- Atypical Teratoid Rhabdoid Tumor (ATRT)Dr. Wernick isExperienced. Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
- Bone TumorDr. Wernick isExperienced. Learn about Bone Tumor.

